Raynaud's phenomenon and other features of scleroderma, including pulmonary hypertension

Research output: Contribution to journalArticle

Abstract

Longitudinal studies of large cohorts of patients with Raynaud's phenomenon have addressed the predictors of developing a secondary disease. New insights have been reported into the pathogenesis of Raynaud's phenomenon and the consequences of ischemia. Studies have suggested that more than one defect may cause Raynaud's phenomenon, including increased α-2 sympathetic receptor activity on vessels, endothelial dysfunction, deficiency of calcitonin gene related peptide protein-containing nerves or some central thermoregulatory defect. The vasoconstricting and profibrotic cytokine endothelin-1 was found to be elevated in scleroderma but did not correlate with disease subset or with evidence of pulmonary hypertension. Oxidant stress is thought to be increased in scleroderma, causing tissue damage and provoking fibrosis. Treatment with infusion of prostacyclin for primary pulmonary hypertension was approved, paving the way for studies of secondary forms of pulmonary hypertension. Oral prostanoids are being tested for the treatment of Raynaud's phenomenon.

Original languageEnglish (US)
Pages (from-to)561-568
Number of pages8
JournalCurrent Opinion in Rheumatology
Volume8
Issue number6
StatePublished - 1996

Fingerprint

Raynaud Disease
Pulmonary Hypertension
Calcitonin Gene-Related Peptide
Endothelin-1
Epoprostenol
Oxidants
Prostaglandins
Longitudinal Studies
Fibrosis
Ischemia
Cytokines
Therapeutics
Proteins

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Raynaud's phenomenon and other features of scleroderma, including pulmonary hypertension. / Wigley, Fredrick.

In: Current Opinion in Rheumatology, Vol. 8, No. 6, 1996, p. 561-568.

Research output: Contribution to journalArticle

@article{10f3ca1c08784f109257f4d9700f50e4,
title = "Raynaud's phenomenon and other features of scleroderma, including pulmonary hypertension",
abstract = "Longitudinal studies of large cohorts of patients with Raynaud's phenomenon have addressed the predictors of developing a secondary disease. New insights have been reported into the pathogenesis of Raynaud's phenomenon and the consequences of ischemia. Studies have suggested that more than one defect may cause Raynaud's phenomenon, including increased α-2 sympathetic receptor activity on vessels, endothelial dysfunction, deficiency of calcitonin gene related peptide protein-containing nerves or some central thermoregulatory defect. The vasoconstricting and profibrotic cytokine endothelin-1 was found to be elevated in scleroderma but did not correlate with disease subset or with evidence of pulmonary hypertension. Oxidant stress is thought to be increased in scleroderma, causing tissue damage and provoking fibrosis. Treatment with infusion of prostacyclin for primary pulmonary hypertension was approved, paving the way for studies of secondary forms of pulmonary hypertension. Oral prostanoids are being tested for the treatment of Raynaud's phenomenon.",
author = "Fredrick Wigley",
year = "1996",
language = "English (US)",
volume = "8",
pages = "561--568",
journal = "Current Opinion in Rheumatology",
issn = "1040-8711",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Raynaud's phenomenon and other features of scleroderma, including pulmonary hypertension

AU - Wigley, Fredrick

PY - 1996

Y1 - 1996

N2 - Longitudinal studies of large cohorts of patients with Raynaud's phenomenon have addressed the predictors of developing a secondary disease. New insights have been reported into the pathogenesis of Raynaud's phenomenon and the consequences of ischemia. Studies have suggested that more than one defect may cause Raynaud's phenomenon, including increased α-2 sympathetic receptor activity on vessels, endothelial dysfunction, deficiency of calcitonin gene related peptide protein-containing nerves or some central thermoregulatory defect. The vasoconstricting and profibrotic cytokine endothelin-1 was found to be elevated in scleroderma but did not correlate with disease subset or with evidence of pulmonary hypertension. Oxidant stress is thought to be increased in scleroderma, causing tissue damage and provoking fibrosis. Treatment with infusion of prostacyclin for primary pulmonary hypertension was approved, paving the way for studies of secondary forms of pulmonary hypertension. Oral prostanoids are being tested for the treatment of Raynaud's phenomenon.

AB - Longitudinal studies of large cohorts of patients with Raynaud's phenomenon have addressed the predictors of developing a secondary disease. New insights have been reported into the pathogenesis of Raynaud's phenomenon and the consequences of ischemia. Studies have suggested that more than one defect may cause Raynaud's phenomenon, including increased α-2 sympathetic receptor activity on vessels, endothelial dysfunction, deficiency of calcitonin gene related peptide protein-containing nerves or some central thermoregulatory defect. The vasoconstricting and profibrotic cytokine endothelin-1 was found to be elevated in scleroderma but did not correlate with disease subset or with evidence of pulmonary hypertension. Oxidant stress is thought to be increased in scleroderma, causing tissue damage and provoking fibrosis. Treatment with infusion of prostacyclin for primary pulmonary hypertension was approved, paving the way for studies of secondary forms of pulmonary hypertension. Oral prostanoids are being tested for the treatment of Raynaud's phenomenon.

UR - http://www.scopus.com/inward/record.url?scp=0030512010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030512010&partnerID=8YFLogxK

M3 - Article

C2 - 9018460

AN - SCOPUS:0030512010

VL - 8

SP - 561

EP - 568

JO - Current Opinion in Rheumatology

JF - Current Opinion in Rheumatology

SN - 1040-8711

IS - 6

ER -